These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 9426083

  • 1. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J.
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [Abstract] [Full Text] [Related]

  • 2. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ, Winter TH, Aalbers R.
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [Abstract] [Full Text] [Related]

  • 3. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
    Richter K, Janicki S, Jörres RA, Magnussen H.
    Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
    Politiek MJ, Boorsma M, Aalbers R.
    Eur Respir J; 1999 May; 13(5):988-92. PubMed ID: 10414394
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.
    van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP.
    Eur Respir J; 1996 Aug; 9(8):1684-8. PubMed ID: 8866595
    [Abstract] [Full Text] [Related]

  • 12. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I, Hall IP, McFarlane LC, Lipworth BJ.
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [Abstract] [Full Text] [Related]

  • 13. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
    Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G.
    Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L, Rosenborg J, Bengtsson T, Lötvall J.
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
    Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, Della Cioppa G.
    Ann Allergy Asthma Immunol; 2001 Jan; 86(1):19-27. PubMed ID: 11206232
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.